MSB 2.17% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-316

  1. 12,336 Posts.
    lightbulb Created with Sketch. 180
    Picked up o the global newswire Xinhua
    - from Nigeria

    https://nnn.com.ng/stem-cell-drug-shows-promise-for-ventilator-dependent-covid-19-patients/


    FOREIGN

    Stem cell drug shows promise for ventilator-dependent COVID-19 patients



    An Australian drug manufacturer has claimed success treating COVID-19 patients who were dependent on ventilators, revealing that seven out of 12 seriously ill patients were discharged from hospital after receiving an experimental stem cell produt

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.